RU2434640C2 - Лечение метастатического рака молочной железы - Google Patents

Лечение метастатического рака молочной железы Download PDF

Info

Publication number
RU2434640C2
RU2434640C2 RU2008130963/15A RU2008130963A RU2434640C2 RU 2434640 C2 RU2434640 C2 RU 2434640C2 RU 2008130963/15 A RU2008130963/15 A RU 2008130963/15A RU 2008130963 A RU2008130963 A RU 2008130963A RU 2434640 C2 RU2434640 C2 RU 2434640C2
Authority
RU
Russia
Prior art keywords
epcam
administered
dose
antibody
breast cancer
Prior art date
Application number
RU2008130963/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2008130963A (ru
Inventor
Карстен РАЙНХАРДТ (DE)
Карстен РАЙНХАРДТ
Роберт САЛЛЕР (DE)
Роберт САЛЛЕР
Original Assignee
Микромет Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Микромет Аг filed Critical Микромет Аг
Publication of RU2008130963A publication Critical patent/RU2008130963A/ru
Application granted granted Critical
Publication of RU2434640C2 publication Critical patent/RU2434640C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2008130963/15A 2006-02-09 2007-02-09 Лечение метастатического рака молочной железы RU2434640C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77242106P 2006-02-09 2006-02-09
US60/772,421 2006-02-09
EP06002680 2006-02-09
EP06002680.4 2006-02-09

Publications (2)

Publication Number Publication Date
RU2008130963A RU2008130963A (ru) 2010-03-20
RU2434640C2 true RU2434640C2 (ru) 2011-11-27

Family

ID=38110762

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008130963/15A RU2434640C2 (ru) 2006-02-09 2007-02-09 Лечение метастатического рака молочной железы

Country Status (9)

Country Link
US (3) US7976842B2 (enExample)
EP (1) EP1981539B1 (enExample)
JP (2) JP2009526770A (enExample)
KR (1) KR101296264B1 (enExample)
AU (1) AU2007213920B2 (enExample)
CA (1) CA2638040A1 (enExample)
IL (1) IL192944A0 (enExample)
RU (1) RU2434640C2 (enExample)
WO (1) WO2007090670A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2007090670A1 (en) * 2006-02-09 2007-08-16 Micromet Ag Treatment of metastatic breast cancer
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
WO2007147074A2 (en) 2006-06-14 2007-12-21 Living Microsystems, Inc. Use of highly parallel snp genotyping for fetal diagnosis
DE102006035617A1 (de) * 2006-07-31 2008-02-21 Siemens Ag Automatische Bestimmung von Tumorlast
US9078888B2 (en) * 2007-01-22 2015-07-14 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
JP5130999B2 (ja) * 2008-03-31 2013-01-30 住友ベークライト株式会社 抗癌剤の有効性予測方法
ES2620294T3 (es) 2008-09-20 2017-06-28 The Board Of Trustees Of The Leland Stanford Junior University Diagnóstico no invasivo de la aneuploidia fetal por secuenciación
WO2011091154A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
BR112013014076A2 (pt) * 2010-12-06 2016-11-22 Cure Cancer Worldwide Corp métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer
CN107903325B (zh) * 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
FR2977674B1 (fr) * 2011-07-06 2015-08-14 Cisbio Bioassays Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US20130179184A1 (en) * 2012-01-06 2013-07-11 Katherine L. Hurst Individualized Dosing Technique With Multiple Variables
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
KR102643443B1 (ko) 2012-11-13 2024-03-06 비온테크 에스이 클라우딘 발현 암 질환의 치료제
US9458245B2 (en) 2013-03-06 2016-10-04 Merrimack Pharmaceuticals, Inc. ANTI-C-MET tandem Fc bispecific antibodies
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015065505A1 (en) * 2013-10-29 2015-05-07 Duke University Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer
US10975164B2 (en) 2018-02-26 2021-04-13 Emory University Antibodies useful for detection of human carcinoma antigen
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2188025C2 (ru) * 2000-07-19 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака молочной железы
RU2195312C2 (ru) * 1996-05-31 2002-12-27 Дзе Скриппс Рисерч Инститьют СПОСОБЫ И КОМПОЗИЦИИ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ИНГИБИРОВАНИЯ αvβ5-ОПОСРЕДОВАННОГО АНГИОГЕНЕЗА
WO2005080428A2 (en) * 2004-02-13 2005-09-01 Micromet Ag Anti-epcam immunoglobulins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
WO2007090670A1 (en) * 2006-02-09 2007-08-16 Micromet Ag Treatment of metastatic breast cancer
PT2520590T (pt) * 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2195312C2 (ru) * 1996-05-31 2002-12-27 Дзе Скриппс Рисерч Инститьют СПОСОБЫ И КОМПОЗИЦИИ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ИНГИБИРОВАНИЯ αvβ5-ОПОСРЕДОВАННОГО АНГИОГЕНЕЗА
RU2188025C2 (ru) * 2000-07-19 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака молочной железы
WO2005080428A2 (en) * 2004-02-13 2005-09-01 Micromet Ag Anti-epcam immunoglobulins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRAUN S et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow // Clin Cancer Res. 1999 Dec; 5(12):3999-4004 он-лайн [найдено в Интернет на (http://clincancerres.aacrjournals.org/content/5/12/3999.full.pdf+html]. *
PRANG N et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines // Br J Cancer. 2005 Jan 31; 92(2):342-9. реферат, он лайн [Найдено в Интернет на www.pubmed.com 10.09.2010], PMID: 15655555 [PubMed - indexed for MEDLINE]. MAKOWER D et al. A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma // Cancer Invest. 2003 Apr; 21(2): 177-84 реферат, он лайн [Найдено в Интернет на www.pubmed.com 10.09.2010], PMID: 12743982 [PubMed - indexed for MEDLINE]. *

Also Published As

Publication number Publication date
IL192944A0 (en) 2009-02-11
US20090304716A1 (en) 2009-12-10
EP1981539A1 (en) 2008-10-22
US20130177578A1 (en) 2013-07-11
EP1981539B1 (en) 2014-07-23
KR101296264B1 (ko) 2013-08-14
JP2013067645A (ja) 2013-04-18
RU2008130963A (ru) 2010-03-20
AU2007213920A1 (en) 2007-08-16
AU2007213920B2 (en) 2013-08-29
US20120009204A1 (en) 2012-01-12
WO2007090670A1 (en) 2007-08-16
US7976842B2 (en) 2011-07-12
JP2009526770A (ja) 2009-07-23
US8337843B2 (en) 2012-12-25
KR20080091817A (ko) 2008-10-14
CA2638040A1 (en) 2007-08-16
US8658172B2 (en) 2014-02-25

Similar Documents

Publication Publication Date Title
RU2434640C2 (ru) Лечение метастатического рака молочной железы
ES2653615T3 (es) Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos
CN104884065B (zh) 治疗癌症的方法
NZ630790A (en) Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP2013067645A5 (enExample)
NZ707377A (en) Combination therapy methods for treating proliferative diseases
EA200701519A1 (ru) Живая аттенуированная ротавирусная вакцина для перорального введения
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2014142220A1 (ja) 抗腫瘍剤
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
Orange et al. Durable regression of primary cutaneous B-cell lymphoma following fever-inducing mistletoe treatment: two case reports
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
Levi et al. Continuous stress disrupts immunostimulatory effects of IL-12
AU2012253610A8 (en) Compositions and methods for treating cancer
RU2008151516A (ru) СПОСОБ УВЕЛИЧЕНИЯ БИОЛОГИЧЕСКОЙ АКТИВНОСТИ ОЧИЩЕННОГО БЕЛКА HspE7
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
CN103861107A (zh) 一种药物组合物及其用途
JP2018522881A5 (enExample)
TR201004720T1 (tr) Majör depresif bozukluğun tedavisi için o-desmetil venlafaksin
CN113117088A (zh) 钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用
CN106668061B (zh) 一种含有顺铂的抗癌药物组合物
EA201491841A1 (ru) Состав эсмолола для парентерального введения
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
JP7034521B1 (ja) がんワクチン及びがんワクチンの製造方法

Legal Events

Date Code Title Description
PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20131127

PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160210